CBX663661 1..10 Research Article Novel blood test to predict neoplastic activity in healthy patients and metastatic recurrence after primary tumor resection Mohamed Abdouh1, Dana Hamam1,2, Vincenzo Arena3, Manuel Arena4, Hussam Alamri1,5, and Goffredo Orazio Arena1,6 Abstract We reported that single oncosuppressor-mutated (SOM) cells turn malignant when exposed to cancer patients’ sera. We tested the possibility to incorporate this discovery into a biological platform able to detect cancer in healthy individuals and to predict metastases after tumor resection. Blood was drawn prior to tumor resection and within a year after surgery. Blood samples from healthy individuals or metastatic patients were used as negative and positive controls, respectively. Patients at risk for cancer were included in the screening cohort. Once treated, cells were injected into nonobese diabetic/severe combined immunodeficiency mice to monitor tumor growth. All samples of sera coming from metastatic patients transformed SOM cells into malignant cells. Four samples from screened patients transformed SOM cells. Further clinical tests done on these patients showed the presence of early cancerous lesions despite normal tumor markers. Based on the xenotransplants size, we were able to predict metastasis in three patients before diagnostic tests confirmed the presence of the metastatic lesions. These data show that this serum-based platform has potentials to be used for cancer screening and for identification of patients at risks to develop metastases regardless of the Tumor Node Metastasis (TNM) stage or tumor markers level. Keywords In vitro platform, transformation, metastasis, screening, prediction, patient serum, cell culture Date received: 9 February 2016; accepted: 13 July 2016 Introduction Despite progress in the understanding of the molecular and genetic basis of cancers, cure or even the 5-year survival rate has remained very low due to metastatic disease, which is recognized as the prominent cause of cancer-related death. 1 Understanding the mechanisms underlying the metastatic process is the cornerstone to improve cancer patient survival, and such knowledge is needed to develop new prognostic and diagnostic tools. Traditionally, metastasis is described as a multistage process initiated by cancer cells detachment from the pri- mary tumor site, circulation of the cells in the blood flow, with subsequent homing in distant sites for the establish- ment of secondary foci of disease. 2 In this context, research 1 Cancer Research Program, McGill University Health Centre-Research Institute, Montreal, Quebec, Canada 2 Department of Experimental Surgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada 3 Department of Obstetrics and Gynecology, Santo Bambino Hospital, Catania, Italy 4 Department of Surgical Sciences, Organ Transplantation and Advances Technologies, University of Catania, Catania, Italy. 5 Department of Surgery, King Saud University, Riyadh, Saudi Arabia 6 Department of Surgery, McGill University, St Mary Hospital, Montreal, Quebec, Canada Corresponding Author: Goffredo Orazio Arena, Cancer Research Program, McGill University Health Centre-Research Institute, 1001 Decarie Boulevard, Montreal, Quebec H4A 3J1, Canada. Email: goffredo.arena@mcgill.ca Journal of Circulating Biomarkers Volume 5: 1–10 ª The Author(s) 2016 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/1849454416663661 cbx.sagepub.com Creative Commons CC-BY-NC: This article is distributed under the terms of the Creative Commons Attribution-Non Commercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). mailto:goffredo.arena@mcgill.ca http://www.sagepub.co.uk/journalsPermissions.nav https://doi.org/10.1177/1849454416663661 http://cbx.sagepub.com https://us.sagepub.com/en-us/nam/open-access-at-sage has mainly been focused on the determination of the iden- tity of these circulating tumor cells (CTCs). Nowadays, the detection and molecular characterization of CTCs are one of the most active areas of translational cancer research. 3 If on one hand, tremendous increase in the amount of research, examining the potential clinical utility of CTCs in the management of cancer has been accomplished, on the other hand, the analytical specificity and clinical utility of these detection methods have not been demonstrated unequivocally. 4 Controversies have arisen since reports from different investigators have shown conflicting results regarding the prognostic relevance of CTCs, and their exploitation, as a prognostic marker, is still a subject of many ongoing investigations. 5–9 Furthermore, the lack of correlation between the presence of CTCs and development of metastatic disease has triggered questions regarding the undisputed validity of the ‘‘seed and soil’’ theory. 10 Recent studies have reported that human cancer cells could transfer signaling molecules to target cells predispos- ing them to malignant transformation. 11–13 This suggests that metastases might occur via transfer of biologically active circulating factors, derived from the primary tumor, to susceptible target cells located in distant organs. This alternative theory has been strengthened by the discovery that blood-circulating factors (i.e. cell-free nucleic acids) or factors carried in circulating microvesicles (such as mRNA, micro-RNA, mutated and amplified oncogene sequences and retrotransposon elements) are indeed shed from several types of human tumors and have different biological effects on distinct types of cells. 14–21 The oncogenic potential of circulating factors has been first described in murine immortalized fibroblasts and was called ‘‘genometastasis.’’ 22–24 More recently, we observed that exposing immortalized or single oncosuppressor-mutated (SOM) human cells (i.e. human embryonic kidney 293 (HEK293) cells and breast cancer 1 (BRCA1)-deficient fibro- blasts) to metastatic cancer patients’ serum induced their transformation into malignant cells, confirming the validity of the genometastasis theory in human cells. The above effect was not seen if these cells were exposed to sera coming from healthy patients. 25,26 Cells transformed even when they were exposed to conditioned media obtained from colon cancer cell cultures proving that the oncotransforming factors were actu- ally produced by cancer cells. Based on these observations, we hypothesize that the ability of SOM cells to incorporate cancer factors could constitute the basis of a novel in vitro serum-based platform that could function both as a cancer screening test for healthy patients and as a predictor of metasta- tic recurrence after primary tumor resection in cancer patients. Materials and methods Blood collection and serum preparation Blood samples were collected in vacutainer tubes contain- ing clot-activation additive and a barrier gel to isolate serum (Becton Dickinson, Franklin Lakes, New Jersey, USA). After 60 min clotting at room temperature, tubes were centrifugation at 1500 � g for 15 min. Serum was collected and subjected to a second centrifugation at 2000 � g for 10 min to clear it from contaminating cells. Serum was aliquoted and stored at �80�C until use. Patient categorization Recruitment for this study was conducted at the department of General Surgery at the Royal Victoria Hospital and St Mary’s Hospital (Montreal, Canada), in accordance to an approved ethics protocol by the Ethics Committee of our institution (SDR-10-057). Thirty-seven patients were stud- ied (Table 1). The test was conducted using, as a detecting biological platform, HEK293 cells and BRCA1 knockout (BRCA1-KO) fibroblasts. 26 In the HEK293 group, five patients who had undergone resection of primary cancer and readmitted for treatment of metastatic disease served as positive controls (cases M1–M5). Eight healthy individ- uals (cases C1–C8) were enrolled in the study as a negative control group. The inclusion criteria considered to be enrolled in the healthy cohort were (i) age (30–60-year old), (ii) no signs and symptoms or personal history of cancer, and (iii) family history negative for cancer. Eight patients with clinical suspicion for cancer were enrolled in the screening cohort (cases S1–S8). Sixteen patients admit- ted for resection of different cancers were recruited and monitored for metastatic recurrence (cases F1–F16). In the BRCA1-KO fibroblast group (Table 2), 3 healthy individ- uals were used as negative controls (cases C1–C3), 10 patients with metastatic disease served as positive controls (cases M6–M15), 2 patients (cases S8 and S9) were enrolled in the screening group, and 2 patients (cases F17 and F18) in the monitoring group. Patient medical statuses and follow-up durations (mean ¼ 22 months; range 3–60 months) are summarized in Tables 1 and 2. Blood samples were obtained with written consent from all participants. Cell culture conditions HEK293 cells were from ATCC (Manassas, Virginia, USA). BRCA1-KO fibroblasts were established as described previously. 26 Cells were maintained in recom- mended culture medium until 30% confluence, at which point, they were treated with DMEM-F12 medium (Wisent, Québec, Canada) supplemented with 10% v/v of either cancer patient or control serum filtered through 0.2-mm filters. Half of the media was changed every second day. When the cells reached 80% confluence, they were pas- saged (one in six) using trypsin/ethylenediaminetetraacetic acid (Wisent). To confirm that there was no contamination or carryover of blood-derived cells, aliquots of the culture medium were placed in a culture plate and incubated at 37�C, 5% carbon dioxide. 2 Journal of Circulating Biomarkers Population doubling level calculation Cells were considered at population doubling zero at the first time they were exposed to patient serum-containing culture medium. At every passage, cell number was deter- mined and population doubling level (PDL) was calculated using the following formula: PDL ¼ log(Nh/Ni)/log2, where Nh is the number of cells harvested at the end of the incubation time and Ni is the number of cells inoculated at the beginning of the incubation time. Cumulative PDL was calculated by adding the previously calculated PDL. In vivo tumor growth Five-week-old female nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice (Jackson Labora- tory, Bar Harbor, Maine, USA) were used in compliance with McGill University Health Centre Animal Compliance Office (protocol 2012–7280). Cells growing in log phase were harvested and washed twice with Hank’s balanced salt solution (HBSS). Mice were injected subcutaneously with 2.10 6 cells in 200 ml HBSS/Matrigel mixture. Mice were followed-up daily for any sign of discomfort and tumor Table 1. Clinical profiles of the patients enrolled (HEK293 cells group). Cases ID Blood collection Disease TNM status Transforming potential Metastases Follow-up (months) CEA (ng/ml) C1 – Healthy – No – – – C2 – Healthy – No – – – C3 – Healthy – No – – – C4 – Healthy – No – – – C5 – Healthy – No – – – C6 – Healthy – No – – – C7 – Healthy – No – – – C8 – Healthy – No – – – M1 Post-op (visit 1) CRC LM Yes Yes – – M1-1 Post-op (visit 2) CRC LM Yes Yes – – M2 Post-op PcC LM Yes Yes – – M3 Post-op CRC LM Yes Yes – – M4 Post-op BC LM Yes Yes – – M5 Post-op CRC LM Yes Yes – – S1 – Healthy – No – – – S2 – Healthy – No – – – S3 – Healthy – No – – – S4 – Thyroid cyst Benign No No 6 2.0 S5 Pre-op Panc. Cyst. Carcinoma in situ Yes No 3 1.2 S6 Pre-op CRC T1N1 Yes No 8 1.0 S7 Pre-op Liver mass Benign No No 3 2.0 S8 Pre-op Sigmoid cancer T3N2 Yes No 3 2 F1* Pre-op CRC T3N0 Yes No 7 3 F1 Post-op CRC T3N0 Yes No 7 3.9 F2* Pre-op CRC T3N0 Yes No 7 12 F2 Post-op CRC T3N0 Yes Yes 7 11 F3* Pre-op CRC T3N0 Yes No 6 6.7 F3 Post-op CRC T3N0 Yes No 6 1.4 F4 Post-op CRC T3N2 Yes Yes 3 22 F5 Post-op CRC T3N0 Yes No 4 0.4 F6 Post-op CRC T4N1C Yes No 20 3.7 F7 Post-op CRC T4N0 Yes No 16 1.6 F8 Post-op CRC T3N0 Yes No 12 1.8 F9 Post-op CRC T2N1 No No 48 1.5 F10 Post-op CRC T4N0 Yes No 60 1.3 F11 Post-op CRC T3N0 Yes No 36 0.7 F12 a Post-op CRC T2N0 Yes No 60 1.4 F13 Post-op SBC – Yes No 60 1.6 F14 Post-op CRC T3N0 Yes Yes 60 6.7 F15 Post-op Lymphoma – Yes No 12 – F16 Post-op Lung cancer T1N0 Yes No 6 2.1 BC: breast cancer; CRC: colorectal cancer; LM: liver metastasis; PcC: pancreatic cancer; Panc. cyst.: pancreatic cystic cancer; SBC: small bowel cancer; HEK293: human embryonic kidney 293; CEA: carcinoembryonic antigen. a Patient F12 was suspected to have a metastatic lesion, but the biopsy revealed a nonmalignant lesion. *Blood collected pre-op. Abdouh et al. 3 growth monitoring. Four weeks postinjection, mice were euthanized and tumor size recorded with a caliper. Histological analysis Mice xenotransplants were collected, fixed in 10% buffered formalin, embedded in paraffin, and stained with hematox- ylin and eosin according to standard protocols or processed for immunohistochemistry. Briefly, 5-mm tissue sections were dewaxed in xylene and rehydrated with distilled water. After antigen unmasking, and blocking of endogen- ous peroxidase (3% hydrogen peroxide), the slides were incubated with primary antibodies specific for tumor mar- kers as described previously. 25,26 Labeling was performed using iView DAB Detection Kit (Ventana, Oro Valley, Arizona, USA) on the Ventana automated immunostainer. Sections were counterstained lightly with hematoxylin before mounting. Histological analyses were performed by a certified pathologist who was blinded to the type of cells from which the cancerous masses, which formed in mice, had been derived. Statistical analysis For in vitro cell growth and viability, statistical differences were analyzed using an analysis of variance followed by the Scheffé post hoc test for multiple comparisons. Given that samples distribution was not normal, we applied the nonparametric Wilcoxon rank sum significance test to compare xenotumor sizes obtained with the sera of meta- static and nonmetastatic patients (regardless of groups; screening, control, or confirmed metastatic). To analyze data of the screening test, we ranked all data (tumor volumes) and determined the 0.95 percentile, which helped, set a cutoff. This was set at 0.13 cm 3 , and this value was used as a threshold for metastasis prediction in the screening group. For this purpose, we used 2 � 2 table and Fisher’s exact test. For all these tests, a p value <0.05 was considered statistically significant. Results Cancer patient sera did not affect either cell proliferation or cell viability during in vitro exposure Our previous studies had shown that serum from metastatic cancer patients increased the proliferation and induced the transformation of primed human cells. 25,26 In the present study, we tested the effectiveness of this discovery to be used to develop a biological platform that could be used as a cancer screening tool in healthy individuals and as a way to predict which patients might develop metastases after primary tumor resection. We verified that treated cells had the same growth potential and the same viability at the time when they were injected in NOD/SCID mice to test for their tumorigenic potential. For this purpose, we treated SOM cells for 2 weeks with daily medium refreshment. Every 5 days, cells were collected, counted, and passaged. At every passage, we calculated the PDL in each condition (Figure 1(a) and (b)). In addition, we determined cell via- bility (Figure 1(c)). Independently of the serum used, nei- ther the cumulative PDL nor cell viability varied significantly. These data suggest that treated cells had the same proliferation potential at the end of the in vitro expo- sure regimen. Table 2. Clinical profiles of the patients enrolled (BRCA 1-KO fibroblasts group). Cases ID Blood collection Disease Site of metastasis Transforming potential Metastases Follow-up (months) CEA (ng/ml) C1 – Healthy – No – – – C2 – Healthy – No – – – C3 – Healthy – No – – – M6 Post-op Adrenal cancer Lung Yes Yes – – M7 Post-op BC Lung and liver Yes Yes – – M8 Post-op NET Liver Yes Yes – – M9 Post-op BC Liver Yes Yes – – M10 Post-op CRC Liver Yes Yes – – M11 Post-op Anal SCC Liver Yes Yes – – M12 Post-op CRC Liver Yes Yes – – M13 Post-op CRC Liver Yes Yes – – M14 Post-op CRC Liver Yes Yes – – M15 Post-op CRC Liver Yes Yes – – S9 Pre-op PcC Peritoneal carcinomatosis Yes Yes 3 40 S8 Pre-op CRC – Yes No 3 2 F17 Post-op CRC Liver Yes Yes 5 6 F18 Post-op Lung cancer – Yes No 3 2 BC: breast cancer; CRC: colorectal cancer; PcC: pancreatic cancer; SCC: squamous cell carcinoma; NET: neuroendocrine tumor; BRCA1-KO: breast cancer 1 knockout; CEA: carcinoembryonic antigen. 4 Journal of Circulating Biomarkers Validation of the efficacy of the SOM cell platform as cancer screening test To validate the accuracy of our SOM cell-based blood test, we recruited nine patients with clinical suspicion of cancer and we enrolled them in the screening group. Eight cases were tested on HEK293 cells (cases S1–S8), and two patients (cases S8 and S9) were tested on BRCA1-KO fibroblasts. One patient was tested with both types of cells (case S8). Fifteen patients (cases M1–M5 in the HEK293 group and cases M6–M15 in the BRCA1-KO fibroblast group) who had undergone resection of primary cancer and readmitted for treatment of metastatic disease were used as positive controls. One patient was tested twice at an inter- val of about 3 years (case M1 and M1-1 in the HEK293 group). At the end of the in vitro treatments, cells were injected subcutaneously in NOD/SCID mice and tumor growth was monitored. Once tumors were palpable, their diameters were measured (Figure 2(b) and (c)). In addition, tumor volumes were calculated at euthanasia (Figure 3). Four of nine patients that were screened with the SOM cell platform transformed the SOM cells into cancer (cases S5, S6, S8, and S9). Upon further investigations, case S9 was found to have elevated carbohydrate antigen 19-9 (CA 19-9) and pancreatic cancer. Case S6 was found to have a large sessile polyp in the colon and normal carcinoembryo- nic antigen (CEA). Pathological analysis of the resected colon showed a T1N1 colon cancer. Case S5 on computed tomography (CT) scan was found to have large pancreatic cysts and normal CA 19-9. Because of the size of the cyst, despite normal tumor markers, the patient underwent a subtotal pancreatectomy, whose pathological analysis showed pancreatic cancer in situ. Case S8 upon further investigations was found to have a mass in the sigmoid colon and normal CEA. The pathology analysis of the resected specimen showed a T3N2 colon cancer. In summary, four of four patients that were positive at the SOM cell platform test were found to have cancer despite normal tumor markers. The other five patients who were negative at the SOM cell test were still investigated to rule out neoplastic disease. While three of them (cases S1–S3) were also negative when screened with conventional tests (serum values, imaging tests), the other two patients were found to have a thyroid nodule concerning for cancer (case S4) and a liver mass (case S7). Upon further investigations, the thyroid nodule was found to be benign as predicted from the SOM platform. The concerning features of the liver mass prompted a surgical resection of the liver whose pathology showed a benign atypical hemangioma, confirm- ing the accuracy of the SOM platform results. Altogether, these findings suggest that SOM cells are capable to sense cancer-produced factors even when tumor markers are negative and suggest that this in vitro blood serum-based platform might be used as a screening test to rule out neoplastic disorders. SOM cells accurately respond to the presence of circulating cancer factors in metastatic disease and transform into cancer All sera from patients with metastases transformed the SOM cells as confirmed by tumor formation following transplantation in NOD/SCID mice (Fisher’s exact test, p < 0.01; Tables 1 and 2, Figures 2(b), 3, and 4). Histo- pathological analyses of the HEK293 cells derived tumors showed that they had identical histological appearances and the types of tumors grown were not dependent of the patient’s type of cancer. The histology confirmed that most tumors were poorly differentiated carcinomas with a high mitotic index (over 90%) and small foci of necrosis (Figure 2(e)). Attempts to characterize these tumors 0 20 40 60 80 100 (c) C el l vi ab il it y (% ) 0 2 4 6 8 10 12 14 16 18 0 5 10 15 Screening Metastatic Control Monitoring (a) C u m u la ti ve p op u la ti on d ou b li n gs Culture duration (days) 0 2 4 6 8 10 12 14 16 18 (b) C u m u la ti ve p op u la ti on d ou b li n gs Figure 1. Cell growth and viability were not affected during in vitro treatment duration. Cells were cultured for 2 weeks in human serum as stated in the legend. (a) and (b) Cell growth was analyzed by counting the number of viable cells at every passage (5 days duration for every passage). (a) Line graph shows the population doublings capability and (b) column graph represents cumulative population doublings at the end of the in vitro treatment periods. The ordinate axis are the same in (a) and (b). (c) Cell viability was calculated as the percentage of viable cells over total counted cells using trypan blue exclusion dye. Data are mean + SD (p > 0.05). Abdouh et al. 5 immunohistochemically failed to show any more differen- tiating features. On the other hand and strikingly enough, histopatholo- gical analyses of the BRCA1-KO fibroblasts showed full differentiation of the cells into colon and pancreatic cancer when they were exposed to colon cancer serum and pan- creatic cancer serum, respectively, proving the hypothesis that SOM cells are able to integrate cancer factors in their genome. 26 The in vitro blood test was able to predict patients at risk for metastases Based on the evidence that the sera of metastatic patients gave rise to tumor significantly greater than those obtained with the sera of nonmetastatic patients (Wilcoxon rank sum test, p < 0.01; Figure 3(a)) and given the fact that the same trend was observed when we analyzed the xenotransplants obtained with cells treated with the sera of patients enrolled for the monitoring study (Wilcoxon rank sum test, p < 0.01; Figure 3(b)), we asked whether the size of the xenotrans- plants could be utilized as a predictor for future metastatic recurrence. We ranked all the xenotransplants according to the tumor volumes and determined the 0.95 percentile. This allowed the determination of a cutoff value that was set at 0.13 cm 3 . This value was used as a threshold for metas- tasis prediction in patients enrolled in the monitoring group. In this cohort of patients, we tested our in vitro cell- based platform with sera of 18 patients (cases F1–F18; Tables 1 and 2). Three of 15 patients (cases F1–F3) under- went the HEK293 test with blood drawn prior and after surgical resection of the tumor. The sera of all tested (a) Control Days after inoculation Days after inoculation Days after inoculation (c) Screening(b) Metastatic (e). Metastatic MonitoringScreening 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 0 5 10 15 20 25 30 C1 C2 C3 C4 C5 C6 C7 C8 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 0 5 10 15 20 25 30 S1 S2 S3 S4 S5 S6 S7 S8 (d) Monitoring T u m or d ia m et er ( cm ) T u m or d ia m et er ( cm ) T u m or d ia m et er ( cm ) T u m or d ia m et er ( cm ) Days after inoculation 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 0 5 10 15 20 25 30 F1* F2* F3* F4 F6 F8 F10 F12 F14 F16 F1 F2 F3 F5 F7 F9 F11 F13 F15 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.4 0 5 10 15 20 25 30 M1 M2 M3 M4 M5 M1-1 Figure 2. Time course of xenotransplants growth. (a) to (c) HEK293 cells were cultured for 2 weeks in human serum as stated in the figure. Cells were injected subcutaneously in NOD/SCID mice and tumor growth was monitored every second day. Once tumors were palpable, their diameters were measured (a) to (d), and their volumes at euthanasia were calculated (see Figure 3). Values are mean + SD (n ¼ 2–3 mice per group). Representative pictures of tumors obtained are shown. (e) Formalin-fixed paraffin-embedded xeno- transplant samples were processed for H&E staining. HEK293: human embryonic kidney 293; NOD/SCID: nonobese diabetic/severe combined immunodeficiency; H&E: hematoxylin and eosin. 6 Journal of Circulating Biomarkers patients, but one (case F9), still retained their oncotrans- forming abilities even after 5 years from primary tumor resection. When we measured the size of the xenotrans- plants, we noticed that sera of patients who had no signs of metastasis generated xenotransplants with sizes smaller than 0.13 cm 3 (0.04 + 0.02 cm3; range 0.01–0.08 cm3; Figure 3(b) and (c)). In contrast, in the HEK293 group, the sera of five patients (cases F1–F4 and F14) gave rise to xenotransplants larger than 0.13 cm 3 (0.18 + 0.12 cm3; range 0.14–0.47 cm3; Figure 3(b) and (c)). Four of them displayed metastatic dis- ease (cases F1, F2, F4, and F14). Statistical analysis showed that xenotransplants volume and metastasis are dependent variables (Figure 3(b), Fisher’s exact test, p < 0.01). Three of the five patients had serum drawn also prior to surgical resection (cases F1–F3). When we compared the size of the xenotransplants, in these patients, we noticed that the size of the xenotransplants had not decreased after surgical resec- tion but it had actually increased in two of them (cases F1 and F2). One of them (case F2) developed metastases at 7 months after the resection. The other patient (case F1) has been found to have CEA values higher than normal and is currently monitored every 3 months with CT scans to rule out metastatic recurrence (Table 1). Case F3 had the test (c) (a) (b) T u m or v ol u m e (c m 3 ) No metastasis (n = 32) 0.6 Metastasis (n = 9) 0.4 0.2 0.0 0.8 1.0 T u m or v ol u m e (c m 3 ) No metastasis (n = 24) 0.3 Metastasis (n = 3) 0.2 0.1 0.0 0.4 Control Metastatic Screening T u m or v ol u m e (c m 3 ) 0.9 C1 0.6 0.3 0.0 Monitoring Patients who developed metastasis C2 C3 C4 C5 C6 C7 C8 M1-1M1 M2 M3 M5M4 S1 1.0 S2 S3 S4 S5 S6 S7 S8 F1 * F1 F2 * F2 F3 * F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 F14 F15 F16 Figure 3. Effect of patient serum on the tumorigenicity of HEK293 cells. HEK293 cells were cultured for 2 weeks in human serum as stated in the figure. Cells were injected subcutaneously in NOD/SCID mice. Four weeks after injection, growing tumors were excised and their volumes were calculated. (a) Whisker plot for the size of the xenotransplants obtained with cells treated with the sera of patients who developed metastasis and those who did not, regardless of the groups (control, metastatic, screening, or monitoring). Note that metastatic patients’ sera gave rise to tumor significantly greater than those obtained with the sera of nonmetastatic patients (p < 0.01). (b) Whisker plot for the size of the xenotransplants obtained when the analysis was done using only xenotransplants obtained with cells treated with the sera of patients in the monitoring group. Note that metastatic patients’ sera gave rise to tumor significantly greater than those obtained with the sera of nonmetastatic patients (p < 0.01). (c) Barres plot showing xenotransplants obtained for each individual involved in the study. Values are mean + SD (n ¼ tumors obtained with 2–3 mice per group). The line represents the threshold for metastasis prediction (set at 0.13 cm3). *Blood collected pre-op. HEK293: human embryonic kidney 293; NOD/SCID: nonobese diabetic/severe combined immunodeficiency. Abdouh et al. 7 repeated 6 months after surgery and it was noted that the size of the xenotransplants obtained with the serum this time was below the metastatic risk threshold compatible with her T3N0 stage. Interestingly, the serum of one patient (case F12) who was diagnosed with metastatic lesions in the liver induced only a slight transformation of HEK293 cells with size of the xenotransplants not typical for metastatic disease but more in keeping with nonactive neoplastic disease. After surgical resection, the pathology of the liver revealed that the lesion in the liver was not malignant as predicted by the HEK293 test (Table 1 and Figure 3(c)). Together, these data indicate that SOM cells are capable to sense cancer-produced factors even after the primary tumors have been removed and suggest a possible use of this biological platform as a way to identify patients at risks to develop metastases after primary cancer resection. Discussion Recently, our group reported that SOM cells turn into malignant cells when exposed to sera of patients with meta- static cancer. The above effect was not seen if SOM cells were exposed to sera coming from healthy patients. 25,26 In the present study, our goal was to test the hypothesis that cells with a single oncosuppressor mutation might be used to identify cancer factors circulating in the blood and explore the potential to incorporate this discovery into a serum-based platform that could be used to both screen healthy patients for cancer disease and to predict which patients might develop metastases after primary tumor resection. To confirm the validity of this hypothesis and the accuracy of this in vitro blood test, we used the sera of four different cohorts of patients: patients with established metastatic diagnosis, healthy donors with no history or sign of cancer, patients with clinical suspicion of cancer, and patients with resected cancer disease. The results of the tests in the screening group proved the effectiveness of this SOM cell platform to detect cancer- circulating material even at early stages and regardless of the presence of positive tumor markers. The ability of the test to predict pancreatic cancer in situ and early colon cancer seems promising since none of the blood tests avail- able nowadays has shown such sensitivity. The negative pathology results shown on the two patients who were taken to surgery for strongly suspicious lesions strengthen the evidence that this test has great potentials to be also highly specific. For these reasons, it seems that the ability of SOM cells to ‘‘sense’’ neoplastic factors in the blood might help redefining new diagnostic approaches to cancer disease incorporating high sensitivity and high specificity in a single test effective at detecting different types of cancers, in different organs. We called this novel test Metastatic And Transforming Elements Released Discovery platform (MATER-D plat- form) to highlight the newly found evidence that SOM cells are truly able to detect cancer factors circulating in the serum of patients, integrate them in their genome, and undergo malignant transformation. 25,26 The observation that sera of patients who had cancer resection and are cancer free still retains its oncotransform- ing ability on the SOM cells, even after 5 years, paves the way to fascinating hypotheses. Speculations can be made that cancer cells or circulating mutated oncogenes are still present in the body even after resection of the primary tumor, as already shown in other studies 27,28 but the gnineercScitatsateMlortnoC T u m or v ol u m e (c m 3 ) 3 C1 2 1 0 Monitoring Patients who developed metastasis C2 C3 M6 M7 M8 M9 M10 M11 M12 M13 M15M14 4 S8S9 F17F18 Figure 4. Effect of patient serum on the tumorigenicity of BRCA1-deficient fibroblasts. Cells were cultured for 2 weeks in human serum as stated in the figure. Cells were injected subcutaneously in NOD/SCID mice. Four weeks after injection, growing tumors were excised and their volumes were calculated. Barres plot display xenotransplants obtained for each individual involved in the study. Values are mean + SD (n ¼ tumors obtained with 2–3 mice per group). NOD/SCID: nonobese diabetic/severe combined immunodeficiency; BRCA1: breast cancer 1. 8 Journal of Circulating Biomarkers oncogenic potential of these factors is counterbalanced by homeostatic processes such as the immune system, with mechanisms still unknown to us. The size of the cancerous xenografts could be viewed as a reflection of the efficiency of these mechanisms, with larger xenografts representing failure of the protective mechanisms to control the prolif- eration of the cancer cells. In our small study, the formation in the HEK293 group of malignant xenografts larger than 0.13 cm 3 was correlated with a higher risk to develop metastases after surgical resection regardless of the TNM stage of the tumor. The evidence that in one patient (case F3) the size of the xenografts were above the metastatic threshold to then fall down below it after surgery, strengthen our belief that the size of the xenografts might be a valid representative of the effectiveness of the treat- ment and an indicator of the interaction between cancer and the body defensive mechanisms. We couldn’t extrapolate any metastatic risk value in the BRCA1-KO fibroblast group due to the small number of patients enrolled in this cohort. We are currently running parallel experiments with both groups of SOM cells to verify the presence of any statistically significant value in the BRCA1-KO fibroblast group. Our recent discovery that BRCA1-KO fibroblasts fully differentiate into colon and pancreatic cancers when exposed to sera of patients with colon and pancreatic can- cer, respectively, strengthens the notion proved herein that SOM cells are able to incorporate genetic material in their genome and undergo malignant transformation. Identifica- tion of the oncogenic factors responsible for the malignant transformation of the SOM cells would be the next natural step to better understand the role of these hypothetical fac- tors in cancer disease and metastatic recurrence. Putative factors that might be implicated in the observed effects and which are being currently investigated, in order to develop new diagnostic tests, are circulating cell-free DNA, or molecules packed in circulating microvesicles. 19,22–24 A growing body of evidence demonstrates that cancer cells are capable of generating microvesicles in vivo, whose number and production increase with cancer stages. 11,29– 33 In keeping with that, high levels of circulating micro- vesicles have been associated with poorly differentiated tumors and shorter disease overall survival in patients with colorectal cancer and the degree of malignancy in ovarian cancer. 33,34 We reported recently that oncosuppressor- deficient target cells were significantly more prone to inter- nalize cancer patients’ serum-derived exosomes, when compared to wild-type target cells. 26 This finding suggests that the efficacy of our platform seems to be dependent on the same principle behind the liquid biopsy tests: the detec- tion of mutated genes carried in the blood either as free circulating material or packed in exosomes or microvesi- cles. 11,12,20,21,35–39 Although the results of our experiments are striking, several limitations can be seen in this study such as the small number of patients enrolled so far and the prevalence of mainly colorectal cancer cases. These limitations can be overcome by a proper designed clinical trial, with an ade- quate sample size and more heterogeneous cohorts of can- cer patients. If the validity of the MATER-D platform to detect trans- fecting material in the serum, of both healthy patients and primary cancer-treated patients, is proven with a larger and properly designed trial, primary and tertiary prevention might be incorporated in a single test, making the second- ary prevention efficacious at its best. Furthermore, this cell-based platform might have strong potential to help identifying those circulating biomarkers that can be detected early during cancer formation and possibly during metastatic recurrence. The discovery of these factors would eventually lead to the creation of antibody-based laboratory tests, which might hold strong promise for early detection of cancer in healthy patients and for supporting cancer patient management and monitoring. Acknowledgment We are grateful to Ayat Salman for her assistance with the Ethical Committee approvals. Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was financially supported by Giuseppe Monticciolo. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. References 1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69–90. 2. Nguyen DX, Bos PD and Massagué J. Metastasis: from dis- semination to organ specific colonization. Nat Rev Cancer 2009; 9: 274–284. 3. Danova M, Torchio M and Mazzini G. Isolation of rare cir- culating tumor cells in cancer patients: technical aspects and clinical implications. Expert Rev Mol Diagn 2011; 11(5): 473–485. 4. Alix-Panabières C and Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59(1): 110–118. 5. Cohen SJ, Punt CJ, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic color- ectal cancer. Ann Oncol 2009; 20: 1223–1229. 6. Rahbari NN, Aigner M, Thorlund K, et al. Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer. Gastroenterol- ogy 2010; 138: 1714–1726. Abdouh et al. 9 7. Tewes M, Kasimir-Bauer S, Welt A, et al. Detection of dis- seminated tumor cells in bone marrow and circulating tumor cells in blood of patients with early-stage male breast cancer. J Cancer Res Clin Oncol 2015; 141(1): 87–92. 8. Lalmahomed ZS, Mostert B, Onstenk W, et al. Prognostic value of circulating tumour cells for early recurrence after resection of colorectal liver metastases. Br J Cancer 2015; 112: 556–561. 9. Mikulova V, Cabinakova M, Janatkova I, et al. Detection of circulating tumor cells during follow-up of patients with early breast cancer: clinical utility for monitoring of therapy effi- cacy. Scand J Clin Lab Invest 2014; 74(2): 132–142. 10. Fidler IJ. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer 2003; 3(6): 453–458. 11. Skoj J, Würdinger T, van Rijn S, et al. Glioblastoma micro- vesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol 2008; 10: 1470–1481. 12. Abdel-Mageed ZY, Yang Y, Thomas R, et al. Neoplastic reprogramming of patient-derived adipose stem cells by pros- tate cancer cell-associated exosomes. Stem Cells 2014; 32: 983–997. 13. Venugopal C, Wang XS, Manoranjan B, et al. GBM secre- tome induces transient transformation of human neural pre- cursor cells. J Neurooncol 2012; 109: 457–466. 14. Runz S, Keller S, Rupp C, et al. Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecol Oncol 2007; 107: 563–571. 15. Gaiffe E, Pretet JL, Launay S, et al. Apoptotic HPV positive cancer cells exhibit transforming properties. PLOS ONE 2012; 7: e36766. 16. Hood JL, San RS and Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res 2011; 71: 3792–3801. 17. Peinado H, Alekovi M, Lavotshkin S, et al. Melanoma exo- somes educate bone marrow progenitor cells toward a pro- metastatic phenotype through MET. Nat Med 2012; 18: 883–891. 18. Balaj L, Lessard R, Dai L, et al. Tumour microvesicles con- tain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011; 2: 180. 19. Fleischhacker M and Schmidt B. Circulating nucleic acids (CNAs) and cancer—a survey. Biochim Biophys Acta 2007; 1775(1): 181–232. 20. Harris DA, Patel SH, Gucek M, et al. Exosomes released from breast cancer carcinomas stimulate cell movement. PLoS One 2015: 10(3): e0117495. 21. Mulcahy LA, Pink RC and Carter DR. Routes and mechan- isms of extracellular vesicle uptake. J Extracell Vesicles 2014; 3: 24641. 22. Garca-Olmo D, Garca-Olmo DC, Ontanon J, et al. Tumor DNA circulating in the plasma might play a role in metasta- sis. The hypothesis of the genometastasis. Histol Histopathol 1999; 14: 1159–1164. 23. Garcı́a-Olmo DC, Domı́nguez C, Garcı́a-Arranz M, et al. Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of sus- ceptible cultured cells. Cancer Res 2010; 70: 560–567. 24. Trejo-Becerril1 C, Perez-Cardenas E, Taja-Chayeb L, et al: Cancer progression mediated by horizontal gene transfer in an in vivo model. PLOS One 2012; 7(12): e52754. 25. Abdouh M, Zhou S, Arena V, et al: Transfer of malignant trait to immortalized human cells following exposure to human cancer serum. J Exp Clin Cancer Res 2014; 33(1): 86. 26. Hamam D, Abdouh M, Gao Z-H, et al. Transfer of malignant trait to BRCA1 deficient human fibroblasts following expo- sure to serum of cancer patients. J Exp Clin Cancer Res 2016: 35: 80. 27. Lindforss U, Zetterquist H, Papadogiannakis N, et al. Persis- tence of K-ras mutations in plasma after colorectal tumor resection. Anticancer Res 2005; 25: 657–661. 28. Ryan BM, Lefort F, McManus R, et al. A prospective study of circulating mutant KRAS2 in the serum of patients with col- orectal neoplasia: strong prognostic indicator in postoperative follow up. Gut 2003; 52: 101–108. 29. Bergsmedh A, Szeles A, Henriksson M, et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci U S A 2001; 98: 6407–6411. 30. Al-Nedawi K, Meehan B and Rak J. Microvesicles: Messen- gers and mediators of tumor progression. Cell Cycle 2009; 8: 2014–2018. 31. Logozzi M, De Milito A, Lugini L, et al. High levels of exosomes expressing CD63 and caveolin-1 in plasma of mel- anoma patients. PLoS One 2009; 4: e5219. 32. Peinado H, Lavotshkin S and Lyden D. The secreted factors responsible for premetastatic niche formation: old sayings and new thoughts. Semin Cancer Biol 2011; 21: 139–146. 33. Silva J, Garcia V, Rodriguez M, et al. Analysis of exosome release and its prognostic value in human colorectal cancer. Genes Chromosomes Cancer 2012; 51: 409–418. 34. Taylor DD. MicroRNA signatures of tumor-derived exo- somes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol 2008; 110:13–21. 35. Pant S, Hilton H and Burczynski ME. The multifaceted exo- some: biogenesis, role in normal and aberrant cellular func- tion, and frontiers for pharmacological and biomarker opportunities. Biochem Pharmacol 2012: 83(11): 1484–1494. 36. Colombo M, Raposo G and Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracel- lular vesicles. Annu Rev Cell Dev Biol 2014; 30:255–289. 37. Thery C, Zitvogel L and Amigorena S. Exosomes: composi- tion, biogenesis and function. Nat Rev Immunol 2002: 2: 569–279. 38. Ogorevc E, Kralj-Iglic V and Veranic P. The role of extra- cellular vesicles in phenotypic cancer transformation. Radiol Oncol 2013; 47(3): 197–205. 39. Candelario KM and Steindler DA. The role of extracellular vesicles in the progression of neurodegenerative disease and cancer. Trends Mol Med 2014; 20(7): 368–374. 10 Journal of Circulating Biomarkers << /ASCII85EncodePages false /AllowTransparency false /AutoPositionEPSFiles true /AutoRotatePages /None /Binding /Left /CalGrayProfile (Gray Gamma 2.2) /CalRGBProfile (sRGB IEC61966-2.1) /CalCMYKProfile (U.S. Web Coated \050SWOP\051 v2) /sRGBProfile (sRGB IEC61966-2.1) /CannotEmbedFontPolicy /Warning /CompatibilityLevel 1.3 /CompressObjects /Off /CompressPages true /ConvertImagesToIndexed true /PassThroughJPEGImages false /CreateJDFFile false /CreateJobTicket false /DefaultRenderingIntent /Default /DetectBlends true /DetectCurves 0.1000 /ColorConversionStrategy /LeaveColorUnchanged /DoThumbnails false /EmbedAllFonts true /EmbedOpenType false /ParseICCProfilesInComments true /EmbedJobOptions true /DSCReportingLevel 0 /EmitDSCWarnings false /EndPage -1 /ImageMemory 1048576 /LockDistillerParams true /MaxSubsetPct 100 /Optimize true /OPM 1 /ParseDSCComments true /ParseDSCCommentsForDocInfo true /PreserveCopyPage true /PreserveDICMYKValues true /PreserveEPSInfo true /PreserveFlatness false /PreserveHalftoneInfo false /PreserveOPIComments false /PreserveOverprintSettings true /StartPage 1 /SubsetFonts true /TransferFunctionInfo /Apply /UCRandBGInfo /Remove /UsePrologue false /ColorSettingsFile () /AlwaysEmbed [ true ] /NeverEmbed [ true ] /AntiAliasColorImages false /CropColorImages false /ColorImageMinResolution 266 /ColorImageMinResolutionPolicy /OK /DownsampleColorImages true /ColorImageDownsampleType /Average /ColorImageResolution 175 /ColorImageDepth -1 /ColorImageMinDownsampleDepth 1 /ColorImageDownsampleThreshold 1.50286 /EncodeColorImages true /ColorImageFilter /DCTEncode /AutoFilterColorImages true /ColorImageAutoFilterStrategy /JPEG /ColorACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /ColorImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000ColorACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000ColorImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasGrayImages false /CropGrayImages false /GrayImageMinResolution 266 /GrayImageMinResolutionPolicy /OK /DownsampleGrayImages true /GrayImageDownsampleType /Average /GrayImageResolution 175 /GrayImageDepth -1 /GrayImageMinDownsampleDepth 2 /GrayImageDownsampleThreshold 1.50286 /EncodeGrayImages true /GrayImageFilter /DCTEncode /AutoFilterGrayImages true /GrayImageAutoFilterStrategy /JPEG /GrayACSImageDict << /QFactor 0.40 /HSamples [1 1 1 1] /VSamples [1 1 1 1] >> /GrayImageDict << /QFactor 0.76 /HSamples [2 1 1 2] /VSamples [2 1 1 2] >> /JPEG2000GrayACSImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /JPEG2000GrayImageDict << /TileWidth 256 /TileHeight 256 /Quality 30 >> /AntiAliasMonoImages false /CropMonoImages false /MonoImageMinResolution 900 /MonoImageMinResolutionPolicy /OK /DownsampleMonoImages true /MonoImageDownsampleType /Average /MonoImageResolution 175 /MonoImageDepth -1 /MonoImageDownsampleThreshold 1.50286 /EncodeMonoImages true /MonoImageFilter /CCITTFaxEncode /MonoImageDict << /K -1 >> /AllowPSXObjects false /CheckCompliance [ /None ] /PDFX1aCheck false /PDFX3Check false /PDFXCompliantPDFOnly false /PDFXNoTrimBoxError true /PDFXTrimBoxToMediaBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXSetBleedBoxToMediaBox false /PDFXBleedBoxToTrimBoxOffset [ 0.00000 0.00000 0.00000 0.00000 ] /PDFXOutputIntentProfile (U.S. Web Coated \050SWOP\051 v2) /PDFXOutputConditionIdentifier (CGATS TR 001) /PDFXOutputCondition () /PDFXRegistryName (http://www.color.org) /PDFXTrapped /Unknown /Description << /ENU >> /Namespace [ (Adobe) (Common) (1.0) ] /OtherNamespaces [ << /AsReaderSpreads false /CropImagesToFrames true /ErrorControl /WarnAndContinue /FlattenerIgnoreSpreadOverrides false /IncludeGuidesGrids false /IncludeNonPrinting false /IncludeSlug false /Namespace [ (Adobe) (InDesign) (4.0) ] /OmitPlacedBitmaps false /OmitPlacedEPS false /OmitPlacedPDF false /SimulateOverprint /Legacy >> << /AllowImageBreaks true /AllowTableBreaks true /ExpandPage false /HonorBaseURL true /HonorRolloverEffect false /IgnoreHTMLPageBreaks false /IncludeHeaderFooter false /MarginOffset [ 0 0 0 0 ] /MetadataAuthor () /MetadataKeywords () /MetadataSubject () /MetadataTitle () /MetricPageSize [ 0 0 ] /MetricUnit /inch /MobileCompatible 0 /Namespace [ (Adobe) (GoLive) (8.0) ] /OpenZoomToHTMLFontSize false /PageOrientation /Portrait /RemoveBackground false /ShrinkContent true /TreatColorsAs /MainMonitorColors /UseEmbeddedProfiles false /UseHTMLTitleAsMetadata true >> << /AddBleedMarks false /AddColorBars false /AddCropMarks false /AddPageInfo false /AddRegMarks false /BleedOffset [ 9 9 9 9 ] /ConvertColors /ConvertToRGB /DestinationProfileName (sRGB IEC61966-2.1) /DestinationProfileSelector /UseName /Downsample16BitImages true /FlattenerPreset << /ClipComplexRegions true /ConvertStrokesToOutlines false /ConvertTextToOutlines false /GradientResolution 300 /LineArtTextResolution 1200 /PresetName ([High Resolution]) /PresetSelector /HighResolution /RasterVectorBalance 1 >> /FormElements true /GenerateStructure false /IncludeBookmarks false /IncludeHyperlinks false /IncludeInteractive false /IncludeLayers false /IncludeProfiles true /MarksOffset 9 /MarksWeight 0.125000 /MultimediaHandling /UseObjectSettings /Namespace [ (Adobe) (CreativeSuite) (2.0) ] /PDFXOutputIntentProfileSelector /DocumentCMYK /PageMarksFile /RomanDefault /PreserveEditing true /UntaggedCMYKHandling /UseDocumentProfile /UntaggedRGBHandling /UseDocumentProfile /UseDocumentBleed false >> ] /SyntheticBoldness 1.000000 >> setdistillerparams << /HWResolution [288 288] /PageSize [612.000 792.000] >> setpagedevice